Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 87492 refers to the detection of the infectious agent Chlamydia trachomatis through nucleic acid techniques, specifically focusing on the quantification of the organism's DNA or RNA. This method is crucial for identifying Chlamydia trachomatis infections, which are classified as sexually transmitted diseases (STDs). Often asymptomatic, these infections can lead to severe complications, particularly in females, where they may cause irreversible damage to the reproductive system, potentially resulting in infertility. In males, while symptoms such as burning and itching of the urethra may occur, they typically do not experience long-term reproductive issues from the infection. The quantification process involved in this code allows healthcare providers to assess the severity of the infection and monitor the effectiveness of treatment. Various nucleic acid testing methods, including direct probe, amplified probe, and quantification techniques, are employed to ensure accurate detection of the pathogen. Specimens for testing are usually collected via swabs from the cervix, male urethra, or eye, and the specific methodology can vary depending on the test kit utilized, which may include advanced techniques such as polymerase chain reaction (PCR) for amplification of the nucleic acids when low levels of the organism are suspected.
© Copyright 2026 Coding Ahead. All rights reserved.
The procedure associated with CPT® Code 87492 is indicated for the detection and quantification of Chlamydia trachomatis infections. The following conditions and symptoms may warrant the use of this test:
The procedure for CPT® Code 87492 involves several key steps to ensure accurate detection and quantification of Chlamydia trachomatis. The following procedural steps are typically followed:
After the procedure associated with CPT® Code 87492, healthcare providers may offer guidance on follow-up care and treatment options based on the test results. Patients may be advised to return for further evaluation if the test indicates a positive result for Chlamydia trachomatis. Treatment typically involves antibiotics, and it is essential for sexual partners to be tested and treated as well to prevent reinfection. Additionally, patients may be counseled on safe sexual practices to reduce the risk of future infections. Regular follow-up testing may be recommended to monitor the effectiveness of treatment and ensure the infection has been cleared.
| Short Descr | CHLMYD TRACH DNA QUANT | Medium Descr | IADNA CHLAMYDIA TRACHOMATIS QUANTIFICATION | Long Descr | Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, quantification | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 206 - Microscopic examination (bacterial smear, culture, toxicology) |
| 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | GA | Waiver of liability statement issued as required by payer policy, individual case | GW | Service not related to the hospice patient's terminal condition | XU | Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2022-01-01 | Changed | Short description changed. |
| 2022-01-01 | Note | Short description changed. |
| 2011-01-01 | Changed | Short description changed. |
| 1998-01-01 | Added | First appearance in code book in 1998. |
Get instant expert-level medical coding assistance.